Home

Matthew L Sherman

CIK 1325710 · EVP & Chief Medical Officer · last filed 2024-06-11

Matthew L Sherman is an EVP & Chief Medical Officer who has filed 77 SEC Form 4 insider transactions across 5 companies since 2013. The most recent filing, for DCPH, was dated Jun 11, 2024. Across all open-market trades the lifetime net is −$7.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $168 across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$168

Companies

5

Total Filings

77

Lifetime Open-Market Net

-$7.83M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Deciphera Pharmaceuticals, Inc. (DCPH) Delisted EVP & Chief Medical Officer 0 $25.59 $0 -$445.2K 21 2024-06-11
PALVELLA THERAPEUTICS, INC. (PIRS) Delisted Director — $13.60 — $0 7 2023-06-23
LUMOS PHARMA, INC. (NLNK) Delisted Director — — — $0 3 2019-08-02
PULM Director 100 $1.68 $168 $0 5 2019-05-20
ACCELERON PHARMA INC (XLRN) Delisted EVP & Chief Medical Officer 77,267 $178.75 $13.81M -$7.39M 41 2018-04-04

Recent Filings

77 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2024-06-11 Deciphera Pharmaceuticals, Inc. (DCPH) Delisted Mixed −110,133 $0 EDGAR
2024-02-20 Deciphera Pharmaceuticals, Inc. (DCPH) Delisted Mixed +14,660 -$40.8K EDGAR
2024-01-18 Deciphera Pharmaceuticals, Inc. (DCPH) Delisted Sell (S) −2,435 -$35.2K EDGAR
2023-12-14 Deciphera Pharmaceuticals, Inc. (DCPH) Delisted Mixed +5,452 -$42.9K EDGAR
2023-10-31 Deciphera Pharmaceuticals, Inc. (DCPH) Delisted Mixed +5,884 -$28.4K EDGAR
2023-10-04 Deciphera Pharmaceuticals, Inc. (DCPH) Delisted Sell (S) −2,942 -$37.3K EDGAR
2023-06-23 PALVELLA THERAPEUTICS, INC. (PIRS) Delisted Grant (A) — $0 EDGAR
2023-06-21 Deciphera Pharmaceuticals, Inc. (DCPH) Delisted Sell (S) −1,655 -$23.8K EDGAR
2023-02-17 Deciphera Pharmaceuticals, Inc. (DCPH) Delisted Mixed +15,517 -$14.7K EDGAR
2023-01-19 Deciphera Pharmaceuticals, Inc. (DCPH) Delisted Sell (S) −2,403 -$51.0K EDGAR
Showing 1–10 of 77
Page 1 of 8
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.